Nasdaq
$1.76▲ 4.14%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $39.9MShares out 22.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 10.13After-hours26.10.14 05:536-KKey event#●●●#●●●#●●●
BIOHARVEST SCIENCES INC.Bullish
BioHarvest Sciences has achieved commercial readiness for its proprietary Olive Cell composition, developed through its Botanical Synthesis technology. The asset has completed the self-affirmed GRAS process in the U.S. and is now available for licensing and commercialization through the company's CDMO business.…more
$1.76+4.14%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.8Regular26.10.09 03:316-KKey event
BIOHARVEST SCIENCES INC.
BioHarvest Sciences has reached a key milestone in its next-generation sweetener development program with Tate & Lyle. This achievement demonstrates that BioHarvest's Botanical Synthesis platform is capable of producing the targeted sweetening solution, further strengthening the ongoing collaboration between the two companies.…more
$1.76+4.14%vs prev closeView filingShare - 10.2Pre-market26.10.02 07:10filed6-KKey event
BIOHARVEST SCIENCES INC.
BioHarvest Sciences has authorized a share repurchase program (NCIB) to buy back up to 5% of its outstanding common shares, totaling 1,133,392 shares. The program will be executed on the Nasdaq over the next 12 months, as the Board believes the current market price does not fully reflect the company's underlying value and growth prospects.…more
$1.76+4.14%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.13Pre-market26.10.13 20:23#●●●#●●●
BioHarvest Sciences' Olive Cell Composition Ready for Licensing
BioHarvest Sciences has completed the development and commercial-scale manufacturing of its proprietary olive-derived composition. While the asset shows potential in preclinical liver health models, the lack of specific commercial contracts warrants a neutral outlook.…more
$1.76+4.14%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.8Pre-market26.10.08 21:06
●●●●●●●● ●●●●● ●●●●●●
BioHarvest Sciences and Tate & Lyle have successfully demonstrated the production of a targeted sweetener through their joint development program. The impact on future revenue remains to be seen as specific commercialization details were not disclosed.…more
$1.76+4.14%vs prev closeShareBenzinga - 9.29Pre-market26.09.29 20:09
●●●●●●●● ●●●●● ●●●●●●
BioHarvest Sciences has authorized a share repurchase program to buy back up to 5% of its outstanding common shares, citing that the current market price does not fully reflect the company's value. The repurchased shares will be retired, serving as a strategic capital allocation to enhance shareholder value.…more
$1.76+4.14%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report